secwatch.observer — SEC 8-K summary
======================================

Issuer:     First Tracks Biotherapeutics, Inc. (TRAX)
CIK:        0002091349
Form:       8-K
Filed at:   2026-04-03T23:59:59+00:00
Accession:  0001193125-26-140835
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

First Tracks Biotherapeutics spin-off from AnaptysBio effective April 20; $80M PIPE at $13.81/sh
--------------------------------------------------------------------------------

- Spin-off of biopharma assets: holders receive 1 share TRAX per ANAB share held on April 6 record date.
- First Tracks starts with ~$180M cash and two-year runway; pipeline includes ANB033, rosnilimab, ANB101.
- Concurrent $80M private placement: 5.79M shares at $13.81/sh to close after spin-off; Leerink & Barclays as placement agents.
- Expected when-issued trading under TRAXV from April 6; regular-way TRAX trading starts April 20 on Nasdaq.
- Spin-off expected to be a taxable transaction for U.S. federal income tax purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2091349/000119312526140835/0001193125-26-140835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2091349/000119312526140835/d111394d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-140835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer